ZYDUSLIFEPharmaceuticals
Zydus Lifesciences Ltd — Cash Flow Statement
₹871.20
+0.00%
Zydus Lifesciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 5.06K Cr | 2.29K Cr | 1.66K Cr | 901.90 Cr | — |
| Repurchase Of Capital Stock | 0.00 | -725.00 Cr | -863.20 Cr | 0.00 | — |
| Repayment Of Debt | 0.00 | -82.70 Cr | -996.00 Cr | -1.42K Cr | — |
| Capital Expenditure | -1.71K Cr | -906.60 Cr | -1.03K Cr | -1.20K Cr | — |
| End Cash Position | 826.80 Cr | 413.00 Cr | 487.80 Cr | 1.11K Cr | — |
| Other Cash Adjustment Outside Changein Cash | 16.60 Cr | 6.00 Cr | — | -25.90 Cr | -107.90 Cr |
| Beginning Cash Position | 413.00 Cr | 487.80 Cr | 657.80 Cr | 888.30 Cr | — |
| Effect Of Exchange Rate Changes | -21.40 Cr | -23.10 Cr | 6.60 Cr | 8.60 Cr | — |
| Changes In Cash | 418.60 Cr | -57.70 Cr | -176.60 Cr | 235.90 Cr | — |
| Financing Cash Flow | 2.01K Cr | -1.78K Cr | -4.40K Cr | -868.30 Cr | — |
| Net Other Financing Charges | -89.50 Cr | -41.30 Cr | — | — | 854.60 Cr |
| Interest Paid Cff | -89.50 Cr | -41.30 Cr | -126.20 Cr | -111.10 Cr | — |
| Cash Dividends Paid | -302.50 Cr | -621.00 Cr | -267.10 Cr | -372.20 Cr | — |
| Common Stock Dividend Paid | -302.50 Cr | -621.00 Cr | -267.10 Cr | -372.20 Cr | — |
| Net Common Stock Issuance | 0.00 | -725.00 Cr | -863.20 Cr | 0.00 | — |
| Common Stock Payments | 0.00 | -725.00 Cr | -863.20 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | 2.40K Cr | -392.90 Cr | -3.15K Cr | -383.70 Cr | — |
| Net Short Term Debt Issuance | 2.40K Cr | -310.20 Cr | -2.31K Cr | 290.70 Cr | — |
| Net Long Term Debt Issuance | 0.00 | -82.70 Cr | -840.80 Cr | -674.40 Cr | — |
| Long Term Debt Payments | 0.00 | -82.70 Cr | -996.00 Cr | -1.42K Cr | — |
| Investing Cash Flow | -8.37K Cr | -1.48K Cr | 1.53K Cr | -1.00K Cr | — |
| Interest Received Cfi | 181.50 Cr | 127.40 Cr | 76.50 Cr | 58.20 Cr | — |
| Dividends Received Cfi | 1.00 Cr | 1.30 Cr | 1.10 Cr | 0.80 Cr | — |
| Net Investment Purchase And Sale | -5.80K Cr | -1.80 Cr | 2.45K Cr | -2.86K Cr | — |
| Sale Of Investment | 216.00 Cr | 462.70 Cr | 2.46K Cr | 0.00 | — |
| Purchase Of Investment | -6.01K Cr | -464.50 Cr | -10.40 Cr | -2.86K Cr | — |
| Net Business Purchase And Sale | -1.02K Cr | -720.10 Cr | 0.00 | 0.00 | — |
| Sale Of Business | 18.50 Cr | 0.00 | — | 0.00 | 103.50 Cr |
| Purchase Of Business | -1.04K Cr | -720.10 Cr | 0.00 | — | 0.00 |
| Net PPE Purchase And Sale | -1.66K Cr | -882.90 Cr | -991.50 Cr | -1.17K Cr | — |
| Sale Of PPE | 51.40 Cr | 23.70 Cr | 39.40 Cr | 35.40 Cr | — |
| Purchase Of PPE | -1.71K Cr | -906.60 Cr | -1.03K Cr | -1.20K Cr | — |
| Operating Cash Flow | 6.78K Cr | 3.20K Cr | 2.69K Cr | 2.10K Cr | — |
| Taxes Refund Paid | -1.80K Cr | -1.29K Cr | -592.00 Cr | -674.60 Cr | — |
| Change In Working Capital | 1.53K Cr | -902.70 Cr | -235.80 Cr | -336.00 Cr | — |
| Change In Other Current Liabilities | 511.10 Cr | 35.50 Cr | 196.90 Cr | 194.70 Cr | — |
| Change In Other Current Assets | 110.90 Cr | -141.40 Cr | 145.90 Cr | 296.80 Cr | — |
| Change In Payable | 98.60 Cr | -47.60 Cr | -170.80 Cr | -120.30 Cr | — |
| Change In Inventory | -444.90 Cr | -2.00 Cr | 440.70 Cr | -525.50 Cr | — |
| Change In Receivables | 1.26K Cr | -747.20 Cr | -848.50 Cr | -181.70 Cr | — |
| Other Non Cash Items | 194.50 Cr | -37.00 Cr | 654.00 Cr | -2.54K Cr | — |
| Provisionand Write Offof Assets | 91.70 Cr | 40.10 Cr | -21.50 Cr | 33.60 Cr | — |
| Depreciation And Amortization | 915.80 Cr | 764.10 Cr | 722.70 Cr | 736.10 Cr | — |
| Amortization Cash Flow | 226.10 Cr | 129.20 Cr | 107.10 Cr | — | — |
| Depreciation | 689.70 Cr | 634.90 Cr | 615.60 Cr | 736.10 Cr | — |
| Pension And Employee Benefit Expense | 16.70 Cr | 20.70 Cr | -29.80 Cr | 32.70 Cr | — |
| Gain Loss On Investment Securities | -40.90 Cr | -139.80 Cr | -60.70 Cr | -88.20 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -137.90 Cr | -88.30 Cr | -312.10 Cr | -296.40 Cr | — |
| Gain Loss On Sale Of PPE | -34.50 Cr | -13.40 Cr | -20.80 Cr | 1.70 Cr | — |
| Net Income From Continuing Operations | 6.03K Cr | 4.84K Cr | 2.58K Cr | 5.23K Cr | — |
| Issuance Of Debt | — | 0.00 | 155.20 Cr | 746.40 Cr | 0.00 |
| Long Term Debt Issuance | — | 0.00 | 155.20 Cr | 746.40 Cr | 0.00 |
| Net Other Investing Changes | — | — | 12.50 Cr | 2.86K Cr | — |
| Net Intangibles Purchase And Sale | — | — | 0.00 | 112.70 Cr | 0.00 |
| Sale Of Intangibles | — | — | 0.00 | 112.70 Cr | 0.00 |
| Issuance Of Capital Stock | — | — | — | — | 986.60 Cr |
| Common Stock Issuance | — | — | — | — | 986.60 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zydus Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.